Prostate-specific Membrane Antigen: Diagnostics

PET Clin. 2024 Jul;19(3):351-362. doi: 10.1016/j.cpet.2024.03.001. Epub 2024 May 3.

Abstract

Since its clinical introduction in May 2011, prostate-specific membrane antigen (PSMA)-PET/computed tomography has quickly gained worldwide recognition as a significant breakthrough in prostate cancer diagnostics. In the meantime, several new PSMA radioligands for PET imaging have been introduced into routine clinical practice. This article aims to introduce the most commonly used tracers and their key areas of application.

Keywords: (18)F-PSMA-1007; (68)Ga-PSMA-11; Imaging; PET; PET/CT; PSMA; Prostate cancer; Prostate-specific membrane antigen.

Publication types

  • Review

MeSH terms

  • Antigens, Surface*
  • Glutamate Carboxypeptidase II* / metabolism
  • Humans
  • Male
  • Positron Emission Tomography Computed Tomography* / methods
  • Prostate / diagnostic imaging
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / diagnostic imaging
  • Radiopharmaceuticals*

Substances

  • Glutamate Carboxypeptidase II
  • FOLH1 protein, human
  • Antigens, Surface
  • Radiopharmaceuticals
  • Prostate-Specific Antigen